combat
variola
viru
bioterrorist
attack
desir
develop
noninvas
vaccin
base
vaccinia
tiantan
vtt
strain
histor
use
erad
smallpox
china
gener
modifi
vtt
mvtt
zci
remov
hemagglutinin
gene
bp
genom
region
hindiii
fragment
mvtt
zci
character
host
cell
rang
vitro
preclin
safeti
efficaci
profil
mice
despit
replicationcompet
cell
line
unlik
vtt
mvtt
zci
caus
death
intracrani
inject
bodi
weight
loss
intranas
inocul
mvtt
zci
replic
mous
brain
safe
immunodefici
mice
mvtt
zci
induc
neutral
antibodi
via
intranas
rout
immun
one
time
intranas
immun
protect
anim
challeng
pathogen
vaccinia
wr
strain
studi
establish
proofofconcept
attenu
replic
mvtt
zci
may
serv
safe
noninvas
smallpox
vaccin
candid
smallpox
seriou
contagi
human
infecti
diseas
mortal
rate
caus
agent
smallpox
variola
viru
member
orthopoxviru
genu
aftermath
septemb
anthrax
lace
letter
appear
unit
state
heighten
concern
variola
viru
might
use
agent
bioterror
sinc
specif
treatment
smallpox
effect
prevent
strategi
still
reli
vaccin
current
stockpil
vaccin
howev
issu
relat
advers
event
includ
postvaccin
enceph
pve
encephalomyel
pvem
invas
immun
procedur
also
add
addit
difficulti
mass
vaccin
especi
develop
countri
therefor
remain
critic
determin
whether
safe
effect
replic
vaccinia
strain
gener
noninvas
smallpox
vaccin
smallpox
erad
campaign
extens
use
smallpox
vaccin
china
vaccinia
viru
tiantan
vtt
strain
vtt
also
member
orthopoxviru
genu
sinc
vaccin
vtt
protect
variola
viru
use
hundr
million
chines
peopl
prevent
smallpox
infect
http
wwwwhointemcdiseasessmallpoxsmallpoxeradicationhtml
led
erad
variola
china
logic
vtt
remain
first
choic
stockpil
countri
howev
clinic
safeti
vaccin
neither
care
studi
clearli
document
report
vtt
caus
larger
lesion
intraderm
vaccin
like
virul
wide
use
smallpox
vaccin
lister
wyeth
recent
demonstr
vtt
remain
virul
mice
intranas
inocul
restrict
use
noninvas
vaccin
moreov
virul
vtt
impli
signific
risk
children
also
mani
immun
compromis
adult
recipi
eg
hivaid
cancer
leukemia
lymphoma
multipl
myeloma
etc
therefor
aim
modifi
vtt
develop
safe
mucos
deliver
noninvas
smallpox
vaccin
safe
vaccin
vector
pathogen
parent
vtt
strain
cell
line
describ
previous
cell
line
grown
condit
recommend
american
type
cultur
collect
atcc
rockvil
md
usa
pathogen
vaccinia
wr
strain
purchas
atcc
atcc
propag
vero
cell
viral
stock
purifi
sucros
cushion
centrifug
viru
vivo
test
purifi
sucros
densiti
gradient
centrifug
viral
titer
determin
tradit
plaqueform
assay
use
crystal
violet
stain
vero
cell
mvtt
zci
gener
vero
cell
use
homolog
recombin
method
vero
cell
infect
vtt
subsequ
transfect
shuttl
vector
zci
contain
report
green
fluoresc
protein
gfp
flank
ha
sequenc
homolog
recombin
also
introduc
bp
delet
disrupt
ha
gene
recombin
viru
obtain
pick
gfpposit
plaqu
seven
round
clonal
purif
appli
gener
mvtt
zci
comparison
purpos
vtt
mvtt
zci
propag
purifi
titrat
vero
cell
parallel
vero
cell
infect
vtt
mvtt
zci
multipl
infect
moi
cell
lysat
gener
h
pi
subject
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
carri
antiha
monoclon
antibodi
gener
gift
dr
h
shida
antigfp
polyclon
antibodi
bd
bioscienc
san
jose
ca
usa
respect
previous
describ
vero
cell
infect
purifi
vtt
clone
moi
infect
cell
lyse
three
freez
thaw
cycl
cell
lysat
treat
proteinas
k
final
concentr
ugml
h
cellular
dna
extract
convent
phenolchloroform
method
individu
vtt
gene
amplifi
pcr
pair
specif
primer
follow
ttaatccatggactcataatct
atgggtatacagcacgaattcg
tcatttcgacattaattccttt
atggtgaaaaataataaaataa
caattagtacaccgctatgttt
ttaacaaaataacataaatata
ttagtttttctttacacaattg
atgttacaggctctgttcaaat
ttattggtgtttgtcgactgtc
atggatctgtcacgaattaata
ttattgatgtctacacatcctt
atgcttgcattttgttattcgt
atggcgactaaattagattatg
catcaattcaattttttttctag
pcr
product
visual
agaros
gel
electrophoresi
multistep
growth
condit
cell
infect
moi
l
cultur
medium
contain
fetal
bovin
serum
fb
min
incub
c
cell
wash
three
time
medium
replenish
fresh
cultur
medium
viral
supernat
infect
cell
harvest
h
postinfect
pi
freezethaw
thrice
harvest
sampl
titrat
duplic
vero
cell
determin
celltocel
spread
mvtt
zci
viral
plaqu
detect
immunostain
rabbit
antivtt
serum
use
method
previous
describ
briefli
target
cell
grown
confluenc
infect
pfu
mvtt
zci
vtt
viral
absorpt
min
cell
wash
three
time
cultur
medium
incub
c
addit
h
antibodi
stain
proteina
conjug
horseradish
peroxidas
boster
wuhan
china
use
detect
bound
rabbit
antibodi
color
develop
substrat
solut
contain
l
h
ml
ethanol
satur
dianisidin
sigma
st
loui
mo
usa
ml
pb
normal
rabbit
serum
use
neg
control
determin
cytopath
effect
cpe
target
cell
infect
mvtt
zci
moi
viral
absorpt
min
cell
wash
three
time
cultur
medium
incub
c
addit
h
detect
cpe
inbr
balbc
mous
chosen
assess
mvtt
zci
virul
use
previous
describ
method
group
fiveweek
old
mice
inocul
intranas
pfu
mvtt
zci
ul
pb
viral
virul
subsequ
determin
daili
measur
anim
bodi
weight
chang
period
day
vtt
evalu
condit
comparison
purpos
evalu
pathogen
mvtt
zci
immunodefici
mice
group
four
scid
mice
infect
intraperiton
ip
pfu
mvtt
zci
pfu
vtt
mice
weight
individu
averag
plot
mice
lose
bodi
weight
sacrif
accord
standard
oper
procedur
anim
facil
number
anim
die
infect
also
calcul
uninfect
mice
includ
control
six
group
balbc
mice
femal
male
half
inocul
intracrani
seri
dilut
virus
pfu
mvtt
zci
l
steril
pb
icld
valu
determin
mice
succumb
day
pi
calcul
end
point
use
reedmuench
method
group
balbc
mice
administr
differ
dose
mvtt
zci
vtt
via
intracrani
rout
l
pb
respect
two
mice
group
sacrif
daili
first
day
pi
viral
isol
infecti
virion
brain
inocul
mice
measur
cultur
serial
dilut
tissu
homogen
vero
cell
viral
titer
determin
count
plaqueform
unit
group
scid
mice
inject
intracrani
pfu
mvtt
zci
access
replic
profil
mvtt
zci
brain
immunodefici
mice
determin
serum
neutral
wr
strain
challeng
plaqu
reduct
neutral
assay
use
briefli
pfu
wr
strain
mix
incub
serial
dilut
heatinactiv
mous
sera
h
c
mixtur
transfer
onto
confluent
monolay
vero
cell
plate
incub
min
c
day
viral
plaqu
visual
crystal
violet
stain
count
ic
ic
determin
highest
dilut
mous
serum
gener
viral
plaqu
reduct
understand
immunogen
mvtt
zci
vivo
group
five
balbc
mice
immun
intramuscularli
pfu
mvtt
zci
vtt
respect
control
anim
given
pb
two
addit
group
mice
vaccin
intranas
pfu
mvtt
zci
understand
immunogen
mvtt
zci
via
mucos
rout
three
week
singl
vaccin
serial
dilut
heatinactiv
sera
specimen
subject
plaqu
reduct
neutral
assay
wr
strain
determin
vivo
efficaci
mvtt
zci
challeng
vaccin
anim
day
singl
vaccin
lethal
challeng
dose
pfu
wr
strain
via
intranas
rout
anim
bodi
weight
chang
subsequ
determin
experiment
protocol
approv
committe
use
live
laboratori
anim
gener
attenu
viral
variant
vtt
sought
delet
ha
gene
relat
attenu
variou
vaccinia
virus
new
vtt
variant
name
mvtt
zci
gener
portion
ha
gene
delet
use
homolog
recombin
method
facilit
purif
mvtt
zci
introduc
gene
green
floresc
protein
gfp
delet
site
serial
round
plaqu
clonal
purif
vero
cell
homogen
mvtt
zci
stock
obtain
determin
coexpress
gfp
vaccinia
specif
protein
infect
cell
express
ha
detect
cell
infect
vtt
mvtt
zci
use
haspecif
monoclon
antibodi
gener
gift
dr
h
shida
fig
also
perform
overlap
pcr
screen
analysi
mvtt
zci
genom
comparison
vtt
found
mvtt
zci
contain
larg
bp
genom
delet
left
termin
region
intend
make
fig
delet
confirm
sequenc
analysi
vaccinia
gene
name
base
sequenc
vaccinia
copenhagen
strain
understand
origin
bp
genom
delet
studi
randomli
select
viral
clone
purifi
vtt
hypothes
smallpox
vaccin
vtt
probabl
consist
pool
variant
name
quasispeci
use
pcrscan
method
analyz
vtt
quasispeci
shown
fig
found
vtt
gene
highli
variabl
within
left
termin
region
nine
clone
contain
variou
gene
delet
result
suggest
mvtt
zci
like
deriv
one
vtt
variant
contain
bp
genom
delet
howev
sinc
none
clone
contain
ident
bp
delet
exclud
possibl
vitro
clonal
select
process
vero
cell
may
also
contribut
emerg
mvtt
zci
due
signific
loss
viral
genom
fragment
sought
determin
host
cell
rang
replic
capac
mvtt
zci
vitro
thirteen
cell
type
previous
use
determin
host
cell
rang
vtt
test
mvtt
zci
found
mvtt
zci
replic
mous
cell
semipermiss
way
suggest
replic
complet
restrict
mous
cell
tabl
howev
display
rather
limit
replic
capac
three
cell
line
includ
mdck
deriv
rabbit
canin
rat
respect
tabl
fig
mvtt
zci
seem
replic
mdck
cell
even
singl
round
replic
experi
moi
viral
particl
format
cell
infect
mvtt
zci
electron
microscopi
analysi
data
shown
confirm
observ
determin
level
viral
spread
among
cell
use
immunohistochem
stain
method
shown
fig
celltocel
spread
mvtt
zci
could
found
mdck
cell
sinc
singli
infect
cell
found
h
h
postinfect
pi
data
suggest
celltocel
spread
like
absent
two
cell
line
moreov
low
level
viral
spread
found
cell
small
cluster
infect
cell
identifi
h
pi
fig
control
replic
spread
mvtt
zci
indistinguish
vtt
vero
cell
suggest
ha
gene
gene
region
nonessenti
mvtt
zci
replic
propag
vero
cell
tabl
fig
b
inbr
balbc
mous
chosen
assess
mvtt
zci
virul
use
intranas
inocul
model
describ
previous
other
shown
fig
none
mice
either
experiment
group
die
experiment
period
howev
contrast
vtt
caus
clear
dosedepend
pattern
bodi
weight
loss
mice
infect
mvtt
zci
show
sign
weight
loss
even
pfu
group
result
demonstr
mvtt
zci
attenu
respect
parent
vtt
investig
neurovirul
mvtt
zci
young
balbc
mice
infect
via
intracrani
ic
rout
lethal
dose
icld
determin
use
reedmuench
method
result
icld
consist
intranas
infect
model
mvtt
zci
significantli
attenu
viru
fig
mice
neither
develop
sign
enceph
death
day
observ
even
group
given
highest
dose
pfuper
mous
data
shown
sinc
icld
parent
vtt
pfu
result
demonstr
mvtt
zci
attenu
least
essenti
nonneurovirul
determin
safeti
profil
mvtt
zci
inocul
scid
mice
pfu
mvtt
zci
via
intraperiton
ip
rout
use
previous
publish
method
control
group
mice
receiv
pfu
parent
vtt
pb
shown
fig
anim
receiv
pfu
vtt
die
euthan
due
signific
bodi
weight
loss
accord
standard
oper
procedur
fig
show
averag
surviv
time
vtt
infect
scid
mice
approxim
dosedepend
anim
eventu
succumb
littl
pfu
vtt
contrast
mice
receiv
pfu
mvtt
zci
surviv
continu
gain
bodi
weight
experiment
period
differ
dose
repres
signific
attenu
phenotyp
mvtt
zci
biolog
properti
parent
vtt
previous
describ
fang
et
al
viru
spread
visual
immunostain
h
stain
cell
foci
stain
cell
foci
stain
cell
foci
stain
cell
carrol
moss
b
cpe
categor
follow
criteria
differ
control
cpe
cpe
cpe
high
level
cell
detach
c
viru
replic
fold
increas
viru
titer
determin
divid
viru
yield
h
practic
input
titer
cell
line
therefor
categor
permiss
p
increas
semipermiss
sp
increas
nonpermiss
np
increas
cell
investig
underli
mechan
may
account
attenu
phenotyp
mvtt
zci
analyz
replic
kinet
mvtt
zci
brain
mice
clear
dosedepend
respons
found
mice
infect
parent
vtt
fig
viral
replic
appear
peak
around
day
pi
interestingli
mvtt
zci
seem
replic
brain
mice
even
dose
pfu
use
titer
declin
time
might
suggest
inocul
infecti
mvtt
zci
somehow
effect
clear
anim
fig
similar
result
obtain
scid
mice
test
independ
experi
fig
im
im
intramuscular
inocul
intranas
inocul
b
sinc
vtt
kill
mice
via
nab
titer
determin
group
neutral
antibodi
titer
calcul
determin
highest
serum
dilut
serial
dilut
achiev
viral
inhibit
explor
potenti
use
mvtt
zci
smallpox
vaccin
evalu
immunogen
viru
term
induc
neutral
antibodi
pathogen
vaccinia
wr
strain
shown
tabl
one
time
immun
mvtt
zci
induc
system
neutral
antibodi
nab
use
dose
pfu
per
mous
lower
dose
pfu
mvtt
zci
suffici
elicit
detect
level
system
nab
via
either
rout
inocul
compar
vtt
parallel
tabl
higher
dose
mvtt
zci
appar
need
achiev
equival
level
system
nab
respons
understand
vivo
efficaci
mvtt
zci
challeng
vaccin
anim
lethal
challeng
dose
pfu
wr
strain
via
rout
day
singl
intramuscular
im
vaccin
bodi
weight
chang
monitor
day
viral
challeng
fig
unvaccin
mice
began
lose
bodi
weight
three
day
post
challeng
die
infect
sacrif
due
total
bodi
weight
loss
contrari
mvtt
zci
vtt
vaccin
anim
receiv
dose
pfu
complet
protect
weight
loss
fig
moreov
lower
dose
group
pfu
vtt
vaccin
anim
complet
protect
mvtt
zci
also
confer
signific
protect
replic
kinet
mvttzci
mous
brain
group
balbc
mice
inocul
intracrani
indic
dose
vtt
mvttzci
b
respect
anoth
group
scid
mice
given
mvttzci
c
two
mice
group
sacrif
daili
first
day
pi
titer
viru
brain
homogen
determin
vero
cell
use
plaqueform
assay
error
bar
indic
standard
deviat
sd
anim
group
fig
protect
mice
pathogen
vaccinia
wr
strain
challeng
group
five
balbc
mice
immun
pfu
pfu
b
mvttzci
vtt
strain
via
indic
rout
respect
mice
receiv
pb
includ
control
thirti
day
postimmun
mice
challeng
intranas
lethal
dose
pfu
equival
wr
strain
mice
lose
bodi
weight
sacrif
accord
standard
oper
procedur
bodi
weight
chang
repres
mean
valu
group
mice
pi
overtim
error
bar
indic
standard
deviat
sd
anim
group
weight
loss
none
mvtt
zci
vaccin
mice
die
experiment
period
fig
sinc
vtt
lethal
via
vaccin
imposs
use
noninvas
mucos
vaccin
option
howev
possibl
mvtt
zci
two
group
mice
vaccin
rout
pfu
mvtt
zci
thirti
day
singl
vaccin
anim
challeng
pfu
pathogen
wr
strain
via
rout
fig
b
show
mvtt
zci
equal
effect
protect
mice
challeng
wr
strain
follow
vaccin
via
rout
compar
im
vaccin
vaccin
anim
receiv
pfu
complet
protect
weight
loss
mice
receiv
low
dose
pfu
also
significantli
protect
weight
loss
none
mvtt
zci
vaccin
mice
die
experiment
period
mvtt
zci
attenu
variant
vtt
moder
sever
advers
reaction
associ
smallpox
vaccin
current
stockpil
sever
nation
recent
studi
therefor
suggest
none
low
virul
vaccinia
strain
select
vaccin
smallpox
china
vtt
licens
smallpox
vaccin
despit
applic
smallpox
erad
whether
vtt
stockpil
respond
possibl
bioterrorist
attack
attract
debat
previous
demonstr
vtt
less
virul
compar
pathogen
wr
strain
vtt
howev
remain
neurovirul
feasibl
noninvas
mucos
vaccin
report
gener
mvtt
zci
variant
vtt
variant
remain
replicationcompet
sever
mammalian
cell
tabl
caus
bodi
weight
loss
intranas
inocul
death
intracrani
inject
mice
fig
b
significantli
attenu
phenotyp
mvtt
zci
also
evid
immunodefici
scid
mice
high
dose
viral
infect
fig
furthermor
show
nonneurovirul
natur
mvtt
zci
like
due
loss
viral
replic
capac
brain
two
mous
speci
fig
c
therefor
much
improv
safeti
profil
mvtt
zci
made
attract
noninvas
smallpox
vaccin
candid
safe
vaccin
vector
pathogen
attenu
phenotyp
mvtt
zci
sole
determin
ha
gene
previous
demonstr
vaccinia
genom
delet
may
result
gener
highli
attenu
viral
variant
exampl
mva
contain
six
major
genom
delet
render
viru
replic
incompet
mammalian
cell
similar
situat
appli
vaccinia
strain
nyvac
mvtt
zci
differ
mva
nyvac
remain
replicationcompet
mammalian
cell
test
tabl
ha
found
plasma
membran
infect
cell
envelop
extracellular
viru
eev
absent
intracellular
matur
viru
imv
abund
infecti
form
infecti
virion
sever
studi
show
loss
ha
associ
reduc
virul
vaccinia
virus
exampl
mva
major
delet
iii
ha
promot
region
inactiv
ha
gene
abl
attenu
neurovirul
vaccinia
wr
strain
fold
determin
icld
valu
render
viru
replic
incompet
mous
brain
surpris
remov
ha
gene
vtt
result
mvtt
zci
diminish
neurovirul
fig
c
specul
factor
could
play
role
reason
perform
overlap
pcrscan
analysi
mvtt
zci
genom
dna
search
potenti
mutat
especi
correspond
unstabl
delet
region
identifi
mva
found
mvtt
zci
contain
major
bp
genom
delet
hindiii
fragment
left
termin
region
viral
genom
intend
introduc
delet
locat
near
delii
site
mva
besid
ha
sever
gene
delet
region
could
contribut
attenu
phenotyp
mvtt
zci
first
known
enhanc
virul
replic
vaccinia
viru
vivo
second
recogn
host
rang
gene
hr
essenti
support
replic
vaccinia
viru
cell
consist
find
mvtt
zci
becom
replic
incompet
cell
fig
third
probabl
involv
regul
host
nfkb
respons
viru
infect
may
potenti
influenc
inflamm
sever
vaccinia
infect
fourth
gene
immunomodulatori
antiapoptot
gene
inhibit
ifn
intracellular
signal
pathway
prevent
rnadepend
protein
kinas
pkr
activ
thu
delet
vaccinia
viru
may
render
viru
sensit
antivir
effect
ifn
probabl
limit
diseas
progress
vivo
lastli
mitochondrialloc
protein
function
protect
cell
apoptosi
inhibit
cytochrom
c
releas
may
affect
viral
propag
vivo
therefor
attenu
phenotyp
mvtt
zci
like
due
loss
ha
well
sever
critic
gene
bp
delet
region
found
parent
vtt
consist
mani
viral
variant
fig
exclud
possibl
gene
may
also
contribut
attenu
phenotyp
mvtt
zci
futur
studi
requir
full
genom
analysi
mvtt
zci
mvtt
zci
attract
noninvas
smallpox
vaccin
candid
safe
vaccin
vector
pathogen
develop
sever
studi
demonstr
mva
induc
compar
protect
immun
respons
pathogen
vaccinia
viru
infect
small
anim
model
compar
replic
vaccin
strain
recent
studi
also
indic
longev
protect
induc
mva
compar
induc
lister
strain
furthermor
vaccin
two
dose
mva
safe
well
toler
compar
current
avail
smallpox
vaccin
dryvax
human
vaccin
also
produc
compar
cellular
humor
immun
respons
one
dose
dryvax
attenu
vaccin
candid
howev
avail
china
demonstr
mvtt
zci
protect
mice
effect
challeng
pathogen
vaccinia
wr
strain
efficaci
profil
similar
vtt
appar
higher
level
neutral
antibodi
induc
either
vtt
mvtt
zci
contribut
complet
protect
anim
lethal
challeng
pathogen
wr
strain
find
surpris
major
neutral
determin
protein
affect
delet
mvtt
zci
correl
protect
anim
previou
studi
interestingli
although
low
dose
mvtt
zci
pfu
induc
detect
system
neutral
antibodi
wr
strain
vaccin
anim
significantli
protect
fig
reason
low
dose
mvtt
zci
probabl
induc
protect
immun
mechan
effect
protect
cellmedi
mucos
immun
respons
requir
investig
sinc
intranas
inocul
mvtt
zci
equal
effect
compar
intramuscular
inject
studi
establish
proofofconcept
attenu
replic
mvtt
zci
may
serv
safe
noninvas
smallpox
vaccin
candid
critic
element
mass
vaccin
program
develop
countri
includ
china
nation
world
largest
human
popul
recent
studi
indic
aerosol
immun
nonrepl
nyvac
mva
vector
vaccin
safe
simpl
immunogen
would
interest
determin
whether
mvtt
zci
better
sinc
replic
mvttvector
vaccin
induc
higher
level
neutral
antibodi
sarscov
infect
via
io
intraor
inocul
compar
nonrepl
mva
vector
replicationcompet
like
offer
greater
advantag
improv
immunogen
mvttbase
vaccin
moreov
replicationcompet
may
offer
greater
advantag
reduc
dose
frequenc
smallpox
vaccin
primeboost
studi
also
conduct
determin
whether
mvtt
zci
vaccin
prior
vtt
dryvax
would
help
minim
primari
cutan
lesion
side
effort
relat
current
stockpil
vaccin
addit
mvtt
zci
use
safe
replic
vector
develop
mucos
deliver
vaccin
infect
human
immunodefici
viru
avian
influenza
viru
etc
recent
construct
mvtt
sivgp
express
simian
immunodefici
viru
gagpolenv
use
mvtt
zci
vaccin
vector
inocul
pfu
mvtt
sivgp
four
rhesu
macaqu
intranas
inocul
respect
four
macaqu
toler
vaccin
well
without
show
clinic
sign
diseas
therefor
evid
indic
virul
mvtt
zci
quit
differ
nonhuman
primat
compar
mice
proof
safeti
profil
mvtt
zci
human
howev
care
clinic
trial
remain
necessari
end
due
replicationcompet
mvtt
zci
necessari
care
evalu
use
immunocomprom
nonhuman
primat
model
individu
mvtt
zci
base
vaccin
use
immun
therapi
aid
patient
gfp
gene
mvtt
zci
serv
nice
neg
select
marker
gener
recombin
virus
includ
vaccin
develop
human
use
